CIRA’s Community Investment Program grants fund innovative community internet projects to build a resilient, trusted and secure internet for all Canadians.
In 2021, we’re especially looking for initiatives that benefit:
The Law Foundation of Ontario makes grants to advance access to justice. Grants are made to nonprofit organizations that work to benefit the people of Ontario.
Responsive grants enable The Law Foundation of Ontario to fund ideas generated by nonprofit community groups to improve access to justice. Responsive grants aim to encourage new ideas, approaches, and relationships that can help address emerging needs and connect more people to legal information and supports, especially people who are not currently being reached.
The Natural Sciences and Engineering Research Council of Canada (NSERC) is partnering with the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF) to fund collaborative research projects on hydrogen and fuel cell technologies.
This competition aims to fund ten preliminary (one-year) projects. The proposals to NSERC should not exceed CAN$50,000. All project expenditures are subject to the principles and directives governing the appropriate use of grant funds as outlined in the Tri-agency guide on financial administration. You must follow the Tri-agency open access policy, and you are also encouraged to make any publication data resulting from funded projects open access.
The current initiative is designed to fund preliminary (one-year) projects between Canadian academic researchers and their counterparts in German academia and/or federal research institutes. It is expected that these projects will
The FY21 LCRP Investigator-Initiated Translational Research Award mechanism supports translational research that will develop promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinician’s firsthand knowledge of patient care. The ultimate goal of translational research is to move a concept or observation forward into clinical application. However, Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between basic and clinical science.
The FY21 LCRP Clinical Translational Research Partnership Award mechanism supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in lung cancer into clinical applications. This award supports the development of translational research collaborations between two independent, faculty-level (or equivalent) investigators to address a critical problem or question in lung cancer in a manner that would be less readily achievable through separate efforts. One partner in the collaboration must be a research scientist and the other must be a clinician. In addition, one partner in the collaboration is strongly encouraged to be an active duty Service member or Federal employee from a Department of Defense (DoD) military treatment facility or laboratory, or a Department of Veterans Affairs (VA) medical center or research laboratory. It should be clear that both have had equal intellectual input into the design of the research project. Multi-institutional partnerships are encouraged but not required. At least one member of the partnership must have experience either in lung cancer research or lung cancer patient care. A proposed project in which the clinical partner merely supplies tissue samples or access to patients will not meet the intent of this award mechanism.
This mechanism is intended to support a pilot, proof-of-principle, or early-phase clinical trial and associated correlative science. A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of interventions on biomedical or behavioral health-related outcomes. It is expected that the proposed trial will have a welldeveloped rationale, strong preliminary data, trial methodology, and execution plan. Any proposed preclinical studies in addition to the trial should be appropriately justified as to its necessity to inform and interpret trial results and the correlative science. If the proposed research would ultimately require U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) and/or Investigational Device Exemption (IDE) submission, applications must demonstrate availability of, and access to, clinical reagents (e.g., therapeutic molecules) and patient population(s).
| INOVAIT is pleased to announce its upcoming Canada-wide call for applications from industry and academic members for its first open round of pilot funding for collaborative research and development projects in the image-guided therapy (IGT) and artificial intelligence (AI) space. The application period will open on Monday, March 8. INOVAIT is a new pan-Canadian network funded by the Government of Canada and hosted at the Sunnybrook Research Institute with the objective of strengthening Canada’s leadership in the IGT sector by supporting and encouraging collaborative development and the integration of AI and data advances into medical technologies. In this upcoming round of funding, INOVAIT is looking to provide short-term pilot R&D projects in AI and IGT with up to $125,000 in matching funds. The most promising projects will then be eligible for follow-on funding of equal or greater amounts for three subsequent years. This competition is open to Canadian corporations, academic institutions, and not-for-profit organizations; however, each project requires two or more Canadian partners and must actively involve at least one Canadian small and medium enterprise (SME). Applications must be submitted no later than April 15, 2021. Application forms and guidelines, as well as more information, are available online at http://www.inovait.ca If you do not have a partner meeting the competition’s criteria, contact us by email at inovait@sunnybrook.ca and we will help you identify one. |
The Chan Zuckerberg Initiative invites applications in support of open source software projects that are essential to biomedical research. The goal of the program is to support software maintenance, growth, development, and community engagement for these critical tools.
The Alzheimer’s Drug Discovery Foundation (ADDF) and Harrington Discovery Institute have partnered to form the ADDF-Harrington Scholar program. The program recognizes physicians or scientists across the US, Canada and the United Kingdom, who are doing research to develop drugs to prevent, treat and cure Alzheimer’s disease. The award provides funding and drug development support to help bridge the gap between basic discovery and the clinical realm.
Up to 3 ADDF-Harrington Scholars are chosen each year. The award includes:
The Harrington Discovery Institute and its Therapeutics Development team will work closely with the awardee and their affiliated institution to maximize the clinical and commercial potential of the selected project.
The ADDF-Harrington Scholar Award selection committee seeks breakthrough discovery defined by innovation, creativity and potential clinical impact, including:
